文献速递免疫规划

小鼠初免mRNA疫苗后以SARS-CoV-2 RBD蛋白融合大肠杆菌肠毒素A亚单位经鼻加强免疫

Intranasal booster with SARS-CoV-2 RBD protein fused to E. coli enterotoxin a subunit after primary mRNA vaccination in mice.
PubMed 文献 · Vaccine · 2024-10-16

研究在小鼠中比较肌内接种一剂或两剂二价BA.4/5 mRNA疫苗后17周和35周,经鼻加强RBD-LTA/RBD混合蛋白的效果;结果显示经鼻加强维持高水平的抗RBD IgG和中和抗体,与两剂mRNA疫苗方案相当,额外加强显著提高抗体滴度。

要点

  • 经鼻RBD-LTA/RBD加强维持高滴度抗RBD IgG和中和抗体。
  • 经鼻加强诱导的抗体水平与两剂mRNA疫苗方案相当。
  • 额外经鼻加强显著提高抗体滴度,有助长期免疫。

核心结论

  • 初免mRNA疫苗后经鼻RBD-LTA/RBD加强可有效长期维持抗体水平,为长期保护提供有前景的策略。

研究设计与样本

  • 小鼠研究:肌内接种一剂或两剂二价BA.4/5 mRNA疫苗后17周和35周,经鼻加强RBD-LTA/RBD混合蛋白。

主要发现

  • 经鼻RBD-LTA/RBD加强维持高水平的抗RBD IgG和中和抗体,与两剂mRNA疫苗方案诱导的水平相当。
  • 额外RBD-LTA/RBD加强显著增加抗体滴度。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 2019 led to the coronavirus infection diseases 2019 (COVID-19) pandemic, significantly impacting global public health and the economy. Numerous COVID-19 vaccines based on the receptor binding domain (RBD) of SARS-CoV-2 spike protein have been developed, utilizing various protein expression platforms and adjuvant systems. In a previous study, we reported using the direct fusion of the A subunit of type IIb E. coli heat-labile enterotoxin with the SARS-CoV-2 RBD protein (RBD-LTA) as an intranasal vaccine candidate (Hsieh et al., 2023). In this study, we investigated the effects of an intranasal booster of RBD-LTA/RBD mixture proteins after one or two doses of intramuscular bivalent BA.4/5 mRNA vaccination over 17 and 35 weeks. Our results indicate that the intranasal RBD-LTA/RBD mixture proteins booster maintains high levels of anti-RBD IgG and neutralizing antibodies, comparable to those elicited by a two-dose mRNA vaccination regimen. An additional RBD-LTA/RBD mixture proteins booster significantly increased antibody titers, demonstrating the potential of this approach for long-term immunity against SARS-CoV-2. Our findings suggest that combining primary mRNA vaccination with an intranasal RBD-LTA/RBD mixture proteins booster can effectively sustain antibody levels over extended periods, providing a promising strategy for long-term protection against SARS-CoV-2 and its variants.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Hsieh HC, Chen CC, Liu WC, et al. Intranasal booster with SARS-CoV-2 RBD protein fused to E. coli enterotoxin a subunit after primary mRNA vaccination in mice. Vaccine. 2024. PMID: 39413492. doi:10.1016/j.vaccine.2024.126448

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。